1337 studies found for:    Open Studies | "Leukemia"
Show Display Options
RSS Create an RSS feed from your search for:
Open Studies | "Leukemia"
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting Dose Escalation Study of EPZ-5676 in Pediatric Patients With Leukemias Bearing a Rearrangement of the MLL Gene
Conditions: Leukemia;   Acute Myeloid Leukemia;   Acute Lymphocytic Leukemia;   Acute Leukemias
Intervention: Drug: EPZ-5676
2 Recruiting Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment
Conditions: Hairy Cell Leukemia (HCL);   Chronic Lymphocytic Leukemia (CLL);   Non-Hodgkins Lymphoma (NHL);   Cutaneous T Cell Lymphoma (CTCL);   Adult T Cell Lymphoma (ATL)
Intervention:
3 Recruiting Fludarabine Phosphate, Radiation Therapy, and Rituximab in Treating Patients Who Are Undergoing Donor Stem Cell Transplant Followed by Rituximab for High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Conditions: Chronic Lymphocytic Leukemia;   Prolymphocytic Leukemia;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Stage III Chronic Lymphocytic Leukemia;   Stage III Small Lymphocytic Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Small Lymphocytic Lymphoma;   T-Cell Large Granular Lymphocyte Leukemia
Interventions: Drug: Fludarabine Phosphate;   Biological: Rituximab;   Radiation: Total-Body Irradiation;   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Procedure: Peripheral Blood Stem Cell Transplantation;   Drug: Cyclosporine;   Drug: Mycophenolate Mofetil;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
4 Recruiting Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia
Conditions: B-Cell Prolymphocytic Leukemia;   Plasma Cell Leukemia;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Non-Hodgkin Lymphoma;   Recurrent Childhood Hodgkin Lymphoma;   Recurrent Childhood Non-Hodgkin Lymphoma;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Plasma Cell Myeloma;   Recurrent Small Lymphocytic Lymphoma;   Refractory Childhood Hodgkin Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Non-Hodgkin Lymphoma;   Refractory Plasma Cell Myeloma;   Refractory Small Lymphocytic Lymphoma;   T-Cell Prolymphocytic Leukemia;   Waldenstrom Macroglobulinemia
Interventions: Drug: Carmustine;   Drug: Etoposide;   Drug: Cytarabine;   Drug: Fludarabine Phosphate;   Drug: Cyclophosphamide;   Drug: Tacrolimus;   Drug: Mycophenolate Mofetil;   Radiation: Total-Body Irradiation;   Drug: Melphalan;   Procedure: Autologous-Allogeneic Tandem Hematopoietic Stem Cell Transplantation;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Procedure: Allogeneic Bone Marrow Transplantation;   Other: Laboratory Biomarker Analysis;   Procedure: Peripheral Blood Stem Cell Transplantation;   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
5 Not yet recruiting Nivolumab With Ibrutinib for Relapsed, Refractory or High-Risk Untreated Patients With Chronic Lymphocytic Leukemia (CLL)
Conditions: Leukemia;   Chronic Lymphocytic Leukemia
Interventions: Drug: Nivolumab;   Drug: Ibrutinib
6 Recruiting Identifying Prognostic Factors in Frontline FCR for Patients With Chronic Lymphocytic Leukemia (CLL)
Conditions: Chronic Lymphocytic Leukemia;   Leukemia
Interventions: Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: Rituximab
7 Recruiting A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia
Conditions: Chronic Lymphocytic Leukemia;   Leukemia
Interventions: Drug: Ibrutinib;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: Rituximab
8 Recruiting A First-in-Human Phase 1 and Expanded Cohort Study of EPZ-5676 in Advanced Hematologic Malignancies, Including Acute Leukemia With Rearrangement of the MLL Gene
Conditions: Acute Myeloid Leukemia;   Acute Lymphoblastic Leukemia;   Myelodysplastic Syndrome;   Myeloproliferative Disorders
Intervention: Drug: EPZ-5676
9 Recruiting Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction
Conditions: Adult Anaplastic Astrocytoma;   Adult Anaplastic Ependymoma;   Adult Anaplastic Oligodendroglioma;   Adult Brain Stem Glioma;   Adult Ependymoblastoma;   Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma;   Adult Mixed Glioma;   Adult Nasal Type Extranodal NK/T-Cell Lymphoma;   Adult Pineal Gland Astrocytoma;   Adult Solid Neoplasm;   AIDS Related Immunoblastic Lymphoma;   AIDS-Related Burkitt Lymphoma;   AIDS-Related Diffuse Large Cell Lymphoma;   AIDS-Related Diffuse Mixed Cell Lymphoma;   AIDS-Related Diffuse Small Cleaved Cell Lymphoma;   AIDS-Related Hodgkin Lymphoma;   AIDS-Related Lymphoblastic Lymphoma;   AIDS-Related Lymphoma;   AIDS-Related Primary Central Nervous System Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-Cell Lymphoma;   Cutaneous B-Cell Non-Hodgkin Lymphoma;   Extensive Stage Small Cell Lung Carcinoma;   Extra-Adrenal Paraganglioma;   Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue;   Gastrin-Producing Neuroendocrine Tumor;   Hepatic Complication;   Hepatosplenic T-Cell Lymphoma;   Intraocular Lymphoma;   Lung Carcinoid Tumor;   Lymphomatous Involvement of Non-Cutaneous Extranodal Site;   Male Breast Carcinoma;   Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma;   Metastatic Adrenal Gland Pheochromocytoma;   Metastatic Digestive System Neuroendocrine Tumor G1;   Nasal Cavity Inverted Papilloma;   Nodal Marginal Zone Lymphoma;   Olfactory Neuroblastoma;   Pancreatic Glucagonoma;   Pancreatic Insulinoma;   Pancreatic Polypeptide Tumor;   Poorly Differentiated Thyroid Gland Carcinoma;   Recurrent Adrenal Gland Pheochromocytoma;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Brain Neoplasm;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult Soft Tissue Sarcoma;   Recurrent Adult T-Cell Leukemia/Lymphoma;   Recurrent Bladder Carcinoma;   Recurrent Breast Carcinoma;   Recurrent Colon Carcinoma;   Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma;   Recurrent Digestive System Neuroendocrine Tumor G1;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Hypopharyngeal Squamous Cell Carcinoma;   Recurrent Inverted Schneiderian Papilloma;   Recurrent Laryngeal Squamous Cell Carcinoma;   Recurrent Laryngeal Verrucous Carcinoma;   Recurrent Lip and Oral Cavity Squamous Cell Carcinoma;   Recurrent Lip Basal Cell Carcinoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Melanoma;   Recurrent Merkel Cell Carcinoma;   Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary;   Recurrent Mycosis Fungoides and Sezary Syndrome;   Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma;   Recurrent Nasal Type NK/T-Cell Lymphoma;   Recurrent Nasopharyngeal Keratinizing Squamous Cell Carcinoma;   Recurrent Nasopharyngeal Undifferentiated Carcinoma;   Recurrent Non-Small Cell Lung Carcinoma;   Recurrent Olfactory Neuroblastoma;   Recurrent Oral Cavity Adenoid Cystic Carcinoma;   Recurrent Oral Cavity Mucoepidermoid Carcinoma;   Recurrent Oral Cavity Verrucous Carcinoma;   Recurrent Oropharyngeal Squamous Cell Carcinoma;   Recurrent Oropharyngeal Undifferentiated Carcinoma;   Recurrent Pancreatic Carcinoma;   Recurrent Pancreatic Neuroendocrine Carcinoma;   Recurrent Prostate Carcinoma;   Recurrent Rectal Carcinoma;   Recurrent Renal Cell Carcinoma;   Recurrent Salivary Gland Carcinoma;   Recurrent Small Cell Lung Carcinoma;   Recurrent Small Lymphocytic Lymphoma;   Recurrent Thyroid Gland Carcinoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   Regional Adrenal Gland Pheochromocytoma;   Regional Digestive System Neuroendocrine Tumor G1;   Small Intestinal Lymphoma;   Somatostatin-Producing Neuroendocrine Tumor;   Splenic Marginal Zone Lymphoma;   Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary;   Stage III Adult Soft Tissue Sarcoma;   Stage III Bladder Cancer;   Stage III Hypopharyngeal Squamous Cell Carcinoma;   Stage III Laryngeal Squamous Cell Carcinoma;   Stage III Laryngeal Verrucous Carcinoma;   Stage III Lip and Oral Cavity Squamous Cell Carcinoma;   Stage III Lip Basal Cell Carcinoma;   Stage III Major Salivary Gland Carcinoma;   Stage III Merkel Cell Carcinoma;   Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma;   Stage III Nasal Type NK/T-Cell Lymphoma;   Stage III Nasopharyngeal Keratinizing Squamous Cell Carcinoma;   Stage III Nasopharyngeal Undifferentiated Carcinoma;   Stage III Oral Cavity Adenoid Cystic Carcinoma;   Stage III Oral Cavity Mucoepidermoid Carcinoma;   Stage III Oral Cavity Verrucous Carcinoma;   Stage III Oropharyngeal Squamous Cell Carcinoma;   Stage III Oropharyngeal Undifferentiated Carcinoma;   Stage III Pancreatic Cancer;   Stage III Prostate Cancer;   Stage III Renal Cell Cancer;   Stage III Thyroid Gland Follicular Carcinoma;   Stage III Thyroid Gland Papillary Carcinoma;   Stage IIIA Breast Cancer;   Stage IIIA Colon Cancer;   Stage IIIA Non-Small Cell Lung Cancer;   Stage IIIA Rectal Cancer;   Stage IIIA Skin Melanoma;   Stage IIIB Breast Cancer;   Stage IIIB Colon Cancer;   Stage IIIB Non-Small Cell Lung Cancer;   Stage IIIB Rectal Cancer;   Stage IIIB Skin Melanoma;   Stage IIIC Breast Cancer;   Stage IIIC Colon Cancer;   Stage IIIC Rectal Cancer;   Stage IIIC Skin Melanoma;   Stage IV Adult Soft Tissue Sarcoma;   Stage IV Bladder Cancer;   Stage IV Breast Cancer;   Stage IV Hypopharyngeal Squamous Cell Carcinoma;   Stage IV Merkel Cell Carcinoma;   Stage IV Nasal Type NK/T-Cell Lymphoma;   Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma;   Stage IV Nasopharyngeal Undifferentiated Carcinoma;   Stage IV Non-Small Cell Lung Cancer;   Stage IV Pancreatic Cancer;   Stage IV Prostate Cancer;   Stage IV Renal Cell Cancer;   Stage IV Skin Melanoma;   Stage IVA Basal Cell Lip Carcinoma;   Stage IVA Colon Cancer;   Stage IVA Laryngeal Squamous Cell Carcinoma;   Stage IVA Laryngeal Verrucous Carcinoma;   Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma;   Stage IVA Major Salivary Gland Carcinoma;   Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma;   Stage IVA Oral Cavity Adenoid Cystic Carcinoma;   Stage IVA Oral Cavity Mucoepidermoid Carcinoma;   Stage IVA Oral Cavity Verrucous Carcinoma;   Stage IVA Oropharyngeal Squamous Cell Carcinoma;   Stage IVA Oropharyngeal Undifferentiated Carcinoma;   Stage IVA Rectal Cancer;   Stage IVA Thyroid Gland Follicular Carcinoma;   Stage IVA Thyroid Gland Papillary Carcinoma;   Stage IVB Basal Cell Lip Carcinoma;   Stage IVB Colon Cancer;   Stage IVB Laryngeal Squamous Cell Carcinoma;   Stage IVB Laryngeal Verrucous Carcinoma;   Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma;   Stage IVB Major Salivary Gland Carcinoma;   Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma;   Stage IVB Oral Cavity Adenoid Cystic Carcinoma;   Stage IVB Oral Cavity Mucoepidermoid Carcinoma;   Stage IVB Oral Cavity Verrucous Carcinoma;   Stage IVB Oropharyngeal Squamous Cell Carcinoma;   Stage IVB Oropharyngeal Undifferentiated Carcinoma;   Stage IVB Rectal Cancer;   Stage IVB Thyroid Gland Follicular Carcinoma;   Stage IVB Thyroid Gland Papillary Carcinoma;   Stage IVC Basal Cell Lip Carcinoma;   Stage IVC Laryngeal Squamous Cell Carcinoma;   Stage IVC Laryngeal Verrucous Carcinoma;   Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma;   Stage IVC Major Salivary Gland Carcinoma;   Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma;   Stage IVC Oral Cavity Adenoid Cystic Carcinoma;   Stage IVC Oral Cavity Mucoepidermoid Carcinoma;   Stage IVC Oral Cavity Verrucous Carcinoma;   Stage IVC Oropharyngeal Squamous Cell Carcinoma;   Stage IVC Oropharyngeal Undifferentiated Carcinoma;   Stage IVC Thyroid Gland Follicular Carcinoma;   Stage IVC Thyroid Gland Papillary Carcinoma;   T-Cell Large Granular Lymphocyte Leukemia;   Testicular Lymphoma;   Thyroid Gland Medullary Carcinoma;   Thyroid Gland Undifferentiated (Anaplastic) Carcinoma;   Tongue Carcinoma;   Waldenstrom Macroglobulinemia
Interventions: Other: Pharmacological Study;   Drug: Romidepsin
10 Recruiting Safety, Tolerability Study of SG2000 in the Treatment of Advanced Chronic Lymphocytic Leukemia and Acute Myeloid Leukemia
Conditions: Acute Myeloid Leukemia;   Chronic Lymphocytic Leukemia
Intervention: Drug: SG2000
11 Recruiting Study of the Glutaminase Inhibitor CB-839 in Leukemia
Conditions: Acute Myeloid Leukemia (AML);   Acute Lymphocytic Leukemia (ALL)
Intervention: Drug: CB-839
12 Unknown  Treatment Protocol for Relapsed Acute Promyelocytic Leukemia (APL) With Arsenic
Conditions: Relapsed Acute Promyelocytic Leukemia;   Refractory Acute Promyelocytic Leukemia
Interventions: Drug: Arsenic trioxide;   Drug: Trisenox
13 Recruiting Ruxolitinib for Adult T-Cell Leukemia
Conditions: T Cell Leukemia, Adult;   Leukemia, Adult T-Cell;   T Cell Leukemia, HTLV I Associated
Intervention: Drug: Ruxolitinib
14 Recruiting Natural History Study of Monoclonal B Cell Lymphocytosis and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Conditions: B-Cell Chronic Lymphocytic Leukemia;   Monoclonal B-Cell Lymphocytosis;   Lymhoma, Small Lymphocytic;   Chronic Lymphocytic Leukemia
Intervention:
15 Recruiting Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia
Conditions: Chronic Lymphocytic Leukemia in Remission;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Diffuse Large B-Cell Lymphoma
Interventions: Biological: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes;   Other: Laboratory Biomarker Analysis
16 Recruiting Alemtuzumab-Ofatumumab in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia
Conditions: Stage I Chronic Lymphocytic Leukemia;   Stage II Chronic Lymphocytic Leukemia;   Stage III Chronic Lymphocytic Leukemia;   Stage IV Chronic Lymphocytic Leukemia
Interventions: Biological: alemtuzumab;   Biological: ofatumumab;   Procedure: biopsy
17 Recruiting Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Conditions: Prolymphocytic Leukemia;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Small Lymphocytic Lymphoma
Interventions: Drug: Ibrutinib;   Other: Laboratory Biomarker Analysis;   Drug: Lenalidomide;   Other: Pharmacological Study
18 Recruiting Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia
Conditions: Stage I Chronic Lymphocytic Leukemia;   Stage II Chronic Lymphocytic Leukemia;   Stage III Chronic Lymphocytic Leukemia;   Stage IV Chronic Lymphocytic Leukemia
Interventions: Drug: Bendamustine Hydrochloride;   Drug: Ibrutinib;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment;   Biological: Rituximab
19 Recruiting Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Conditions: Anemia;   Fever, Sweat, and Hot Flashes;   Stage I Chronic Lymphocytic Leukemia;   Stage I Small Lymphocytic Lymphoma;   Stage II Chronic Lymphocytic Leukemia;   Stage II Small Lymphocytic Lymphoma;   Stage III Chronic Lymphocytic Leukemia;   Stage III Small Lymphocytic Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Small Lymphocytic Lymphoma;   Weight Change
Interventions: Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Drug: Ibrutinib;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment;   Biological: Rituximab
20 Recruiting PF-04449913 For Patients With Acute Leukemia at High Risk of Relapse After Donor Stem Cell Transplant
Conditions: Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia
Intervention: Drug: Hedgehog inhibitor PF-04449913

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years